Although the advent of two FDA-approved therapies for idiopathic pulmonary fibrosis (IPF) has energized the field, their effects are largely suppressive than pulmonary fibrosis remission-or reversion-inducing. Hence, the pursuit for newer IPF therapeutics continues. Recent studies showed that joint analysis of systems biology level information with drug-disease connectivity are effective in discovery of biologically-relevant candidate therapeutics.
Introduction
Idiopathic pulmonary fibrosis (IPF), a chronic and fatal fibrotic lung disease in people over 50 years old is estimated to affect 14 to 42.7 per 100,000 people (1) . IPF is characterized by progressive subpleural and paraseptal fibrosis, heterogeneous honeycomb cysts (honeycombing), and clusters of fibroblasts and myofibroblasts (2) . The median survival time of patients with IPF is 2.5 to 3.5 years, with 5-year survival rate around 20% (1) . Currently, two small moleculespirfenidone and nintedanib -are approved for IPF and are reported to slow down lung function decline caused by disease progression. However, drug induced side-effect profiles of these two drugs are formidable and their therapeutic effects are suppressive rather than pulmonary fibrosis remission or reversal (3, 4) . The pursuit of relatively safer and efficacious therapies or combinatorials that arrest, or reverse fibrosis therefore continues. On the other hand, technological advances in experimental and computational biology resulted in rapidly expanding genomic and biomedical data, including transcriptomic profiles of disease and small molecules, disease or drug associated pathways and protein-protein interactions (5) (6) (7) . Various approaches have been developed to facilitate in silico drug discovery via joint analysis of these data including the connectivity mapping-based method, a widely used approach (8) .
The concept of connectivity mapping between a drug and a disease is defined as the gene expression-based similarity calculated using a Kolmogorov-Smirnov statistic like algorithm (9, 10) . It was first introduced as the ConnectivityMap (CMap) and succeeded by the LINCS L1000 project and the CLUE platform (8, 11) , which currently contain gene expression profiles of ~20,000 small molecule perturbagens analyzed in up to 72 cell lines. The connectivity mapping concept and application have led to the discovery of novel candidate compounds for disease, drug repurposing candidates, and novel drug mechanism of actions (12) (13) (14) (15) (16) .
Recently similar efforts -in silico drug discovery for IPF -have been reported wherein joint analysis of systems biology level information with drug-IPF connectivity are used to discover biologically relevant candidate therapeutics for IPF. For instance, Karatzas et al developed a scoring formula to evaluate drug-IPF connectivity obtained from multiple sources and identified several IPF candidate therapeutics (17) . Interestingly, neither of the two approved IPF drugs (pirfenidone and nintedanib) was re-discovered by their approach (17) . In another recent study using network-based approach and integrated KEGG network with connectivity analysis sunitinib, dabrafenib and nilotinib were identified as potential repurposing candidates for IPF (18) . Interestingly, the network-based approach was able to re-discover nintedanib. However, the application of this is potentially limited because the construction of the network is based on KEGG pathways and known drug targets only.
Using a similar approach, namely, by examining connectivity between IPF gene signature and LINCS small molecules, we discovered 17-AAG (a known Hsp90 inhibitor) as a potential candidate therapeutic that inhibits fibroblast activation in a mouse model of pulmonary fibrosis (14) . In another related study, we screened connectivity of LINCS small molecules with cystic fibrosis (CF) and integrated systems biology level information from CFTR to identify a candidate drug for cystic fibrosis (13) . These results suggest that disease-drug connectivity complemented with systems biology level information of drugs and disease could facilitate more accurate candidate discovery. In this study we therefore calculated both gene-expression and enriched-pathway based connectivity between IPF and small molecules in an unsupervised manner and integrated these results with cheminformatic knowledge to prioritize candidate therapeutics for IPF. We have identified 77 (out of ~20,000 LINCS small molecules) candidate therapeutics for IPF. Significantly, among these were the approved drug for IPF (nintedanib), as well as several others that are either currently being investigated or reported as a potential candidate therapeutics for IPF (sunitinib and nilotinib). This suggests that the current approach has the potential to identify "true" candidate thereapeutics. Recent in vitro and in vivo preclinical studies have reported beneficial effects of HDAC inhibitors (HDACIs) in preventing or reversing fibrogenesis (19, 20) . Further, there are currently four HDACIs approved by the US FDA for cancer treatment but none for fibrotic diseases. Therefore, in the current study, we have selected entinostat (MS-275 or SNDX-275), a class-I HDACI, from our computational screening results for in vitro validation.
Methods

Cohort selection
We used publicly available gene expression profiles from the Gene Expression Omnibus (GEO) (21) database as a basis for generating IPF gene expression signatures. Since gene expression profiles are known to be heterogeneous in different patients (22, 23) , we selected 6 GEO datasets comparing primary healthy human lung tissues with primary IPF lung tissues for this study to potentially mitigate such heterogeneity ( Table 1 ).
Differential analysis of IPF gene expression profiles
Differential analysis was performed in R in using the package "limma" (24) . Genes with fold change above or equal to 1.5 and adjusted p-value less than or equal to 0.05 were considered differentially expressed. Each dataset was analyzed separately.
IPF-compound connectivity estimation and permutation analysis
To correct for multiple testing problem introduced by conducting connectivity analysis in multiple datasets, we used permutation analysis to estimate the significance of connectivity.
First, we constructed a matrix of connectivity score, denoted by s, between CLUE compound i and IPF dataset d in cell line j. Next, positive and negative connectivity to IPF were determined by thresholding connectivity score at 90 and -90, respectively:
Overall connectivity, denoted by o, between each compound to IPF across all cell lines is summarized as the sum of individual connectivity across all datasets and all cell lines:
Permutation was performed by randomly shuffling rows of the connectivity matrix C, so that compound names were randomly assigned. Then, the permutated overall compound-to-IPF connectivity O' scores were calculated, and we recorded incidences where ‫‬ ‫‬ ', which indicates the observed compound to IPF connectivity is not larger than random connectivity:
We repeated the permutation tests for 100,000 times and estimated significance as the frequency of F overall all permutations. Significance cut-off was set at 0.05.
Functional enrichment
Functional enrichment analysis was performed using the pre-compiled libraries from the ToppGene Suite (25) . Enrichment p values were calculated using hypergeometric test in Python using the scipy package.
Annotation-based connectivity analysis
Annotation-based compound-IPF connectivity was generated and evaluated as follows:
(1) Identify enriched annotation terms enriched in conserved IPF genes (genes that were dysregulated in more than 4 IPF datasets) via functional enrichment analysis, resulting in two vectors, and ;
(2) Calculate enrichment score, , and , , of the 500 highest and lowest expressed genes of each LINCS L1000 small molecule expression profile, denoted by i, in the up-regulated and down-regulated IPF pathways identified in step (1);
(3) Calculate annotation-based connectivity score, defined as Pearson correlation between , and , and between , and ;
(4) To correct false positives from multiple testing, permutation analysis were performed by swapping annotation terms in , and ,
, followed up recalculation of annotationbased connectivity. 100,000 permutations were performed with significance threshold set to 0.05. 
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Result
Differential expression analysis of IPF datasets
We analyzed 6 gene expression datasets comparing gene expression between lung tissue derived from IPF patients and those from healthy controls ( Table 1 ). Differential expression analysis was performed in each dataset using the R package "Limma". Differentially expressed genes (DEG)
were defined as genes with fold change above or equal to 1.5 and FDR-BH adjusted p-value less than or equal to 0.05. The number of DEGs ranged from 263 to 2385, and 4677 genes were unambiguously up-regulated, and 2210 genes were unambiguously down-regulated in at least one IPF dataset (Figure 2a ; Supplementary Table 1 ). Overall similarity between DEG gene lists is low, as is reflected by the median Jaccard index between gene lists of only 0.077. The large discrepancy between datasets suggests disease heterogeneity in IPF but also justifies performing meta-analysis across multiple datasets to extract high confidence drug candidates for IPF. Despite the large heterogeneity in DEG among different IPF datasets, there were also a considerable number of genes that were consistently dysregulated in 4 or more IPF datasets, which we call the conserved IPF gene set (197 up-regulated genes and 84 down-regulated genes). Among these conserved DEGs, 60 genes were known previously to be involved in pulmonary fibrosis (Figure 2b) . Functional enrichment analysis of conserved IPF genes showed that biological processes involved in extracellular matrix formation, inflammation responses and cell migration were up-regulated while processes involved in normal lung processes such as angiogenesis and alveolar functions were down-regulated.
Expression based connectivity analysis and permutation analysis.
We used the NIH Library of Integrated Network-Based Cellular Signatures (LINCS) library as our search space for IPF therapeutic candidates. The LINCS library contains expression profiles of ~20,000 small molecules assayed in various cell lines. To identify potential IPF candidate therapeutics, we adopted the connectivity mapping method which assumes small molecules with gene expression profiles negatively correlated with that of a disease are likely to be therapeutic for the particular disease. We first queried the Connectivity Map web platform (CLUE.io) for compounds with a reversed gene expression profile comparing to IPF. From each dataset, a gene signature containing up to 150 most up-regulated and down-regulated genes was extracted and used to query the CLUE platform (Figure 2c and Supplementary Table 2 ). Using the hits from CLUE results, we applied a "greedy" approach to capture the highest number of compounds connected to IPF by selecting compounds with at least 90 connectivity score in any one of the cell lines. This approach returned 1000+ compounds that are connected with IPF at least once. A problem with this approach is that it introduces many compounds whose connection to IPF is observed in both the directions, i.e., potentially inducing and reversing IPF gene expression profiles at the same time (Figure 3a) . This indicates that the gene expression perturbation due to technical variation is present in our data and is reflected in the form of these low frequency compounds in CLUE analysis. Under the assumption that IPF pathogenesis related gene expression patterns are consistently present in our selected 6 IPF datasets, we performed permutation analysis to estimate the significance of IPF-disease connectivity and filter out false positives. With a significance cut-off at 0.05, we identified 82 compounds that were significantly connected with IPF (Figure 3b) . These compounds were associated with 63 different mechanisms of action.
Functional enrichment-based connectivity analysis
One limitation of using the Touchstone Library based CLUE platform to screen for drug candidates is that it only covers 2,836 out of ~20,000 small molecules in the full L1000 database.
To overcome this, we searched for IPF candidate therapeutics among the remaining ~17,000 LINCS small molecules. To do this, we used a functional enrichment based metric to evaluate drug-IPF connectivity of these LINCS small molecules, wherein gene expression data from both the compound and the IPF data sets were transformed into enrichment p-values using candidates as IPF therapeutic candidates from annotation-based connectivity analysis (Figure 4) .
These compounds include EGFR inhibitor gefitinib, PDGFR and VEGFR inhibitor dovitinib, and KIT inhibitor sunitinib.
Prioritization of IPF candidate therapeutics based on shared mechanism of action
In the annotation-based connectivity analysis, we observed that the several of the ranked compounds shared drug mechanisms of action (MoA). For instance, EGFR inhibition, PDGFR inhibition and VEGFR inhibition were shared across multiple compounds suggesting potential relevance of these MoAs to IPF. This also suggests a likelihood of higher therapeutic potential of multiple compounds with shared and similar MoAs. Leveraging the known MoA information of the discovered compounds, we further prioritized compounds belonging to MoA that were prioritized by annotation-based connectivity analysis. After removing glucocorticoid receptor agonists and immunosuppressants from the list because of their known detrimental effects in IPF, we identified 48 MoAs meeting this criteria ( Supplementary Table 3 ). Based on these MoAs, we selected 77 compounds as our final pre-clinical candidates for IPF ( Supplementary Table 4 ).
Among these, 39 were FDA-approved drugs or phase-II/III compounds suggesting their repositioning potential for IPF ( Table 2) . These drugs include Bcr-Abl kinase inhibitors, EGFR inhibitors, opioid receptor inhibitors, receptor tyrosine kinase (RTK) inhibitors and aurora kinase inhibitors. Notably, the approved IPF drug nintedanib was also among this list. This is important because Nintedanib was not included in the CLUE database, and would have been missed if annotation-based connectivity were not examined. A closer look at the pharmacological targets of these candidates revealed that many of these targets such as PDGFRA, EGFR, FGFR4, FYN and KDR were differentially expressed in IPF. Among these targets, KDR, FGFR4 and PDGFRA are associated with nintedanib and other multi-targeted RTK inhibitors such as dovitinib, pazopanib and sunitinib (Figure 5) . These genes are involved in VEGF and PI3k/AKT signaling and VEGFR2 mediated cell proliferation, suggesting a role for multi-targeted RTK inhibitors in controlling IPF through VEGF signaling inhibition.
Anti-fibrotic potential of entinostat (MS-275 or SNDX-275)
Recent studies have reported the beneficial effects of HDAC inhibitors (HDACIs) in preventing or reversing fibrogenesis. For instance, HDAC8 was reported to contribute to pulmonary fibrosis and NCC170, a HDAC8-selective inhibitor, repressed TGFβ1-induced fibroblast contraction and α -SMA protein expression in normal human lung fibroblasts (19) . Another study reported that vorinostat or SAHA (suberoylanilide hydroxamic acid), a known HDACI, induces apoptosis in IPF fibroblasts (20) . There are currently four HDACIs approved by the US FDA for cancer treatment but none for IPF. Therefore, in the current study, we have selected entinostat (MS-275 or SNDX-275), a class-I HDACI, from our computational screening results for in vitro validation.
Primary lung fibroblasts were isolated from fibrotic lung lesions of TGFα mice and treated with either vehicle or entinostat ( Figure 6 ). We observed a significant reduction in the expression of fibroproliferative genes (CCNA2 and CCNB2), α SMA and KIF20A with MS 275 treatment for 48 hrs compared to vehicle treated fibroblasts ( Figure 6 ). Together, these findings support that anti-fibrotic drugs identified using in silico screening methods are effective in inhibiting fibroblast activation and may serve as potential drug candidates for further validation using both in vitro and in vivo pre-clinical IPF models.
Discussion
In this study, we developed a multiplexed, generalizable approach to discover novel therapeutics by integrating disease-driven and perturbagen-driven gene expression profiles, diseaseassociated biological pathways, and cheminformatics of perturbagen. Compound-IPF connectivity were examined from different dimensions including transcriptome, functional enrichment profiles, and drug mechanisms of actions. With this approach, we not only identified approved IPF therapeutic drugs (nintedanib) but also identified additional FDA-approved drugs that share similar MOA as IPF candidate therapeutics. Notably, these drugs were not discoverable using conventional transcriptome based connectivity analysis alone. Further, approved drugs or investigational compounds associated with MoAs such as Bcr-abl inhibitor and Aurora kinase inhibitor, were also among our candidate list, which could provide insights into novel intervention strategies against IPF.
Transcriptome based connectivity mapping was first introduced more than a decade ago and has been applied to facilitate drug discovery for various diseases, including IPF. In a recent study, Karatzas et al proposed nine drugs as IPF therapeutics based on their connectivity with expression profiles derived from IPF datasets. However, they were not able to re-discover approved IPF drugs although these drugs were included in the LINCS L1000 library that was queried (17) . Likewise, our gene expression based connectivity approach through CLUE prioritized 82 small molecules as IPF therapeutics candidates, but neither of the FDA approved IPF drugs (pirfenidone or nintedanib) was in the list. A closer look at the connectivity scores revealed that pirfenidone had no connectivity to IPF in any of the six queried datasets, although it was connected to 2 of our prioritized IPF candidates, histamine receptor antagonist ranitidine and calcium channel blocker verapamil. On the other hand nintedanib was not included in CLUE and thus no information regarding its connectivity to IPF could be obtained in this way.
We also examined the connectivity between the ~17,000 compounds not covered by CLUE and IPF. The gene expression profiles associated with these small molecules were often from distinct selections of cell lines, and thus direct connectivity mapping analysis may be susceptible to biological variation introduced by cell lines. In addition, it has been shown that integration of prior knowledge, particularly in the form of gene sets information in biological pathways, has been shown to improve the accuracy of drug activity predictions (26) . We evaluated drug-IPF connectivity through enriched pathways directly related to IPF under the assumption that pathways perturbed by drugs are more stable across different host cell conditions compared to individual genes. Annotation-based connectivity analysis lead to discovery of additional 14 small molecules that were not included in the CLUE platform. These include aurora kinase inhibitor barasertib-HQPA and phosphodiesterase inhibitor roflumilast. Notably, nintedanib was also among the 14 additional small molecules, and the enriched pathways that contributed to the connection to IPF were related to fibroblast proliferation, ECM production and cell migration, which is in consistent with implicated MoA of nintedanib against IPF in vitro (27) .
Among the 77 prioritized candidates, 31 are FDA-approved drugs and are associated with different MoAs. These MoAs include RTK inhibition, which is the known MoA for the approved IPF drug nintedanib. Other compounds with this MoA in our discovered candidate compounds included pazopanib and sunitinib. Sunitinib is approved for treatment of renal cell carcinoma and gastrointestinal stromal tumor, and it has also been shown to be efficacious in inhibiting established pulmonary fibrosis in the bleomycin-induced mouse model (28) . Additionally, MoAs involved with these 31 drugs also included those associated with compounds that are currently investigated or are in clinical trial for IPF drugs, such as src-kinase inhibitor and mTOR inhibitor (29) . The MoAs associated with the remaining IPF repositioning candidates included aurora kinase inhibitor, EGFR inhibitor, calcium channel blocker, phosphodiesterase inhibitor, PPAR agonist, Bcr-Abl kinase inhibitors and opioid receptor antagonist.
HDACIs have been reported to improve resolution of pulmonary fibrosis in mice (19, 20) .
Entinostat (MS-275 or SNDX-275), a class I HDACI is currently investigated (Phase II) for metastatic colorectal cancer (30) , breast cancer (31), relapsed and refractory Hodgkin lymphoma (32) , and myeloid malignancies (33, 34) . These ongoing trials, and our preliminary in vitro data, suggests repositioning potential of entinostat in IPF.
In conclusion, we have developed a generalizable, integrative connectivity analysis combining information from transcriptomic profiles, disease systems biology and drug cheminformatics for in silico IPF drug discovery. Application of our approach earlier in the IPF drug discovery pipeline may help to avert late stage clinical trial failures. As almost half the candidates we have discovered in this study are FDA-approved or are currently in clinical trials for a number of diseases, rapid translation of these compounds is feasible. Finally, we have suggested novel drug mechanisms that could shed new insights in the search for better IPF drugs. Works in this study could be summarized in three steps. a) Collection and differential analysis of human IPF datasets; b) Expression-based connectivity analysis through CLUE; c) annotationbased connectivity analysis examining similarity between pathways perturbed by compound and those involved in IPF. 
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